Rearranged during Transfection (RET) Inhibitors [MoA] - N0000193947

Pharmacologic Code	N0000193947
Pharmacologic Name	Rearranged during Transfection (RET) Inhibitors
Pharmacologic Uses	kinase inhibitor
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

The table contains 7 products whose active ingredient are classified under the same pharmacologic class Rearranged during Transfection (RET) Inhibitors [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0002-2980	Retevmo	Non-Proprietary Name: Selpercatinib	Capsule	Oral	Eli Lilly And Company	ACTIVE
	0002-3977	Retevmo	Non-Proprietary Name: Selpercatinib	Capsule	Oral	Eli Lilly And Company	ACTIVE
	0002-5340	Retevmo	Non-Proprietary Name: Selpercatinib	Tablet, Coated	Oral	Eli Lilly And Company	ACTIVE
	0002-5562	Retevmo	Non-Proprietary Name: Selpercatinib	Tablet, Coated	Oral	Eli Lilly And Company	ACTIVE
	0002-6082	Retevmo	Non-Proprietary Name: Selpercatinib	Tablet, Coated	Oral	Eli Lilly And Company	ACTIVE
	0002-6120	Retevmo	Non-Proprietary Name: Selpercatinib	Tablet, Coated	Oral	Eli Lilly And Company	ACTIVE
	50242-210	Gavreto	Non-Proprietary Name: Pralsetinib	Capsule	Oral	Genentech, Inc.	ACTIVE